Evidence map›Paper›PMID 41711750›Full record

ReviewCancer control : journal of the Moffitt Cancer Center

Ubiquitin-Specific Protease 10: A New Target in Tumor Immune Escape.

Jingjing Huang, Ning Li, Jiangang Sun, Xiaojing Li

Abstract readReview
In one paragraph

Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jingjing HuangDepartment of General Surgery, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Ning LiDepartment of Hematology and Oncology, Children's Hospital Affiliated to Zhengzhou University/Henan Children's Hospital/Zhengzhou Children's Hospital, Zhengzhou, Henan, China.
Jiangang SunDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xiaojing LiDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID 0009-0000-2013-9171

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor immune escape is a major challenge in cancer treatment, and targeted immune escape therapy has become a key strategy for cancer treatment. As an important deubiquitinating enzyme, ubiquitin-specific protease 10 (USP10) participates in the process of tumor development by adjusting the balance between ubiquitination and deubiquitination of substrate proteins. Recently, USP10 has been shown to be closely related to tumor immune escape, where it serves to reduce the immunogenicity of tumor cells by stabilizing immune checkpoints and promotes tumor immune escape. In this review, we focus on the structural and functional characteristics of USP10 and elaborate on the biological function of USP10 in the occurrence and development of tumors, as well as its role in immune escape, including the regulation of immune checkpoints and the effect on immune cells in the immune microenvironment. It is possible to improve the efficacy of traditional cancer therapies by appropriately regulating the expression of USP10. The aim of this review is to provide a reference for further understanding the mechanism of tumor immune escape and the development of new tumor treatment methods.

Indexed as

NeoplasmsTumor EscapeUbiquitin ThiolesteraseAnimalsHumansTumor MicroenvironmentUbiquitin ThiolesteraseUSP10 protein, humanimmune checkpoint blockadeinhibitorstargetstherapytumors

Identifiers

PMID41711750
PMCPMC12924933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.